$PGEN

Shah Rutul R sold $251K of PGEN

Shah Rutul R (Chief Operating Officer) sold 42,924 shares of PRECIGEN, INC. (PGEN) at $5.85 ($0.25M total) on 2026-06-29 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Shah Rutul R
Published Jul 1, 2026, 10:21 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 1, 2026, 10:24 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$PGEN
Neutral
high confidence
Mentioned
$PGEN
Relevance
3/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$PGENNeutralLow
01

Why it matters

The only new fact is the disclosed sale size, price, and post-transaction holdings; it does not include guidance, trial results, or regulatory updates.

02

Market read

Traders may monitor insider activity for sentiment, but 10b5-1 sales typically carry less informational weight than unscheduled sales.

03

What to watch

The filing doesn’t disclose reasons for the sale beyond the plan; without accompanying buy/sell patterns or new company events, trading impact should be limited.

Relevance 3/10Novelty 3/10Timing: Filed after-hours on 2026-07-01; reflects sale executed 2026-06-29.

Background

The article is a primary-source SEC Form 4 insider transaction disclosure for Precigen, Inc.

Company-level read

Ticker impact

$PGENNeutralHigh confidence
Context

SEC Form 4 shows COO Shah Rutul R sold 42,924 shares of Precigen at $5.85 on 2026-06-29 under a 10b5-1 plan.

Expected impact

Low likelihood of a sustained price move solely from this disclosure; any reaction is likely muted and short-lived.

Evidence & confidence

The filing is an open-market sale by an officer, explicitly under a pre-arranged 10b5-1 plan, with no new operating, regulatory, or financial datapoints.

Market effects

Minimal; this is company-specific insider transaction with no sector-wide catalyst.

None indicated.

None indicated.

Counterpoint

Because it’s a 10b5-1 plan, the sale may be purely mechanical rather than a bearish view on prospects.

Key entities

  • PRECIGEN, INC.

    Subject of the Form 4 insider transaction disclosure.

  • Shah Rutul R

    Chief Operating Officer who sold shares under a 10b5-1 plan.

Related articles

$PGENMed

PRECIGEN, INC. (PGEN): Results of Operations and Financial Condition

PRECIGEN, INC. (PGEN) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 dp251262_ex9901.htm EXHIBIT 99.1 Exhibit 99.1 Precigen Reports Second Quarter 2026 Financial Results Highlighted by Accelerating PAPZIMEOS Revenue Growth · PAPZIMEOS ® net revenue of $53.1 million in the second quarter of 2026, more than double the prior quarter, reflec

$PGENMedAI 9/10

Precigen Presents New Long-Term Durability Data for PAPZIMEOS, Recently Granted Seven-Year Market Exclusivity, Demonstrating Complete Responses Beyond 4 Years

Precigen (Nasdaq: PGEN) reported updated long-term durability data for PAPZIMEOS (zopapogene imadenovec-drba) in adults with recurrent respiratory papillomatosis. According to the company, 15 of 18 complete responders (83%) had ongoing complete responses for at least 36 months as of April 30, 2026, with 5 beyond 4 years; median duration not yet reached and no new safety events were observed. The FDA granted seven-year orphan drug market exclusivity.

$PGENMedAI 9/10

Precigen Presents New Long-Term Durability Data for PAPZIMEOS, Recently Granted Seven-Year Market Exclusivity, Demonstrating Complete Responses Beyond 4 Years

Precigen (Nasdaq: PGEN) reported updated long-term durability data for PAPZIMEOS (zopapogene imadenovec-drba) in adults with recurrent respiratory papillomatosis (RRP), presented at the 2026 ASCO meeting. As of April 30, 2026, 15 of 18 complete responders (83%) had ongoing complete responses for ≥36 months without additional RRP treatment; 5 responders had responses beyond 4 years. Precigen said no new adverse safety events were observed. The FDA granted PAPZIMEOS seven-year orphan drug market e